Drugs / MVA-BN-Brachyury

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT04296942 May → Oct 2021 HER2 positive breast carcinoma, triple-negative breast carcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT04134312 Jan 2020 → Jan 2021 metastatic neoplasm Bavarian Nordic Completed No outcome recorded
Phase 1 NCT03349983 Jan 2018 → Jun 2020 Bavarian Nordic Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03493945 May 2018 → Oct 2024 castration-resistant prostate carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 23 trials
Phase 2 NCT05445882 Apr 2024 castration-resistant prostate carcinoma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 2 NCT04020094 Nov 2019 → Apr 2021 prostate adenocarcinoma University of Utah Withdrawn No outcome recorded
Phase 2 NCT03595228 Oct 2018 → Dec 2021 chordoma Bavarian Nordic Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as MVA-BN-Brachyury “BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury).” NCT05445882
6

“Each injection of MVA-BN-Brachyury consists of 2.0 x 10(8) infectious units (Inf.U).” NCT04296942

MVA-BN-Brachyury injections will be given on day 0 and 14.” NCT03595228

NCT03349983

NCT04134312

NCT03493945

NCT04020094

Known as MVA-Bavarian Nordic (BN)-Brachyury “Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD)” NCT04296942
Known as MVA-BN-brachyury-TRICOM “Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.” PMID 34479925 Sep 2021
Modality Vaccine “MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines” NCT03349983
Route Subcutaneous “MVA-brachyury s.c., 8 × 108 infectious units (IU)” PMID 31876334 Dec 2019